Article Text

Download PDFPDF

128 Cardiac sarcoidosis: the outcomes of patients undergoing cardiac transplant
Free
  1. Syed Gardezi,
  2. Owais Dar,
  3. Vasilis Kouranos,
  4. Rakesh Sharma
  1. Royal Brompton and Harefied Hospitals NHS Trust (Part of GSTT NHS Foundation Trust), London, UK

Abstract

Background Sarcoidosis is a multi-organ granulomatosis disease. The diagnosis and management of cardiac sarcoidosis (CS) can be challenging and requires an integrated multidisciplinary approach including multi-modality imaging, electrophysiology, devices, advanced heart failure, transplantation and specialist cardiac and pulmonary sarcoidosis teams.PurposeWe aim to assess the presentation, diagnostic approaches and outcomes of patients with CS undergoing cardiac transplantation.

Methods Retrospective observational study. The data of patients undergoing cardiac transplant at Harefield hospital between 1st June 2010 and 30th June 2020 was analysed. Patients with a diagnosis of CS undergoing transplantation were identified from this data.

Results 243 patients underwent cardiac transplant at Harefield hospital between 1st June 2010 and 30th June 2020. 7/243 (3%) patients had an underlying diagnosis of CS. 7/7 (100%) of these were male. CS patients had a higher mean age of presentation as compared to those with without sarcoidosis undergoing transplantation (41+-15 Vs 50+-9.) 5/7 (71%) patients with cardiac sarcoidosis had CRT-D with 1/7 (14%) had CRT-P implantation pre-transplantation. 6/7 (86%) patients underwent both CMR and FDG-PET scans to confirm the diagnosis of cardiac sarcoidosis whereas 1/7 (14%) needing endomyocardial biopsy to confirm the diagnosis prior to undergoing cardiac transplantation. 3/7 (43%) patients had isolated cardiac sarcoidosis while 4/7 (57%) had cardio-pulmonary sarcoidosis (table-1). 4/7 (57%) patients had an initial presentation with ventricular tachycardia whereas 3/7 (43%) presented with a higher degree AV block (figure-1). The diagnosis of cardiac sarcoidosis was confirmed on the histopathological examination of explanted heart in 7/7 patients (100%). 2/7 patients (28%) died with post-transplant complications within the first 2 weeks whereas 5/7 (72%) remain alive; mean post- transplant survival 6 +- 2.5 years thus far. Rather interestingly a relapse of sarcoidosis was noted in the transplanted heart among 2/5 (40%) of surviving post-transplant patients (figure-2) despite of being on the post-transplant immunosuppressive regimen (table-1).

Abstract 128 Figure 1

Initial presentation of patients with Cardiac Sarcoidosis

Abstract 128 Figure 2

The outcomes among surviving Cardiac Sarcoidosis patients post-Transplant

Abstract 128 Table 1

Demographics of patients undergoing Cardiac Transplant. (n = 243)

Conclusion A higher incidence of CS relapse (40%) was noted in transplanted heart of surviving patients despite of being on post cardiac transplant immunosuppressive regimen including Tacrolimus/Sirolimus, MMF and maintenance dose oral Prednisolone (3-5mg).

Conflict of Interest No conflict of interest

  • Cardiac Sarcoidosis
  • Transplantation
  • Immunosupression

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.